Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations

Natasha K. Martin, Peter Vickerman, Alec Miners, Graham R. Foster, Sharon Hutchinson, David Goldberg, Matthew Hickman

Research output: Contribution to journalArticle

Abstract

Injecting drug use is the main risk of hepatitis C virus (HCV) transmission in most developed countries. HCV antiviral treatment (peginterferon-a + ribavirin) has been shown to be cost-effective for patients with no reinfection risk. We examined the cost-effectiveness of providing antiviral treatment for injecting drug users (IDUs) as compared with treating ex/non-IDUs or no treatment.
Original languageEnglish
Pages (from-to)49-57
Number of pages9
JournalHepatology
Volume55
Issue number1
Early online date6 Dec 2011
DOIs
Publication statusPublished - Jan 2012

Keywords

  • hepatitis C
  • antiviral treatment
  • intravenous drug users
  • reinfection risk

Fingerprint Dive into the research topics of 'Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations'. Together they form a unique fingerprint.

  • Cite this